Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14323764 | 0.94 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL1607966 | 0.85 | KCNA3 (0.50) | ALDH1A1MAPTCA12CA1CA9 | |
| SCHEMBL3602803 | 0.85 | CA12 (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL15218250 | 0.82 | CA12 (0.51) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL8392921 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL1395593 | 0.81 | CA12 (0.55) | ALDH1A1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL14275050 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL6914766 | 0.78 | CA12 (0.52) | ALDH1A1SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL7191275 | 0.77 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL4739840 | 0.77 | KCNA3 (0.54) | ALDH1A1CA12CA1CA9KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112293-A1 | Purification Strategy for Direct Nucleophilic Procedures | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112293-A1 | Purification Strategy for Direct Nucleophilic Procedures | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112293-A1 | Purification Strategy for Direct Nucleophilic Procedures | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-12 | — | — | US | disclosed |
| EP-2276717-A1 | PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127372-A1 | PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127372-A1 | PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112293-A1 | Purification Strategy for Direct Nucleophilic Procedures | MLX, SRM, STS | ALDH1A1 974/4885SMN1; SMN2 1590/4885LMNA 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.